Abstract
Acetyl-CoA carboxylases (ACCs) play a rate-limiting role in fatty acid biosynthesis in plants, microbes, mammals and humans. ACCs have the activity of both biotin carboxylase (BC) and carboxyltransferase (CT), catalyzing carboxylation of Acetyl-CoA to malonyl-CoA. In the past years, ACCs have been used as targets for herbicides in agriculture and for drug discovery and development of human diseases, such as microbial infections, diabetes, obesity and cancer. A great number of small molecule ACC inhibitors have been developed, including natural and non-natural (artificial) products. These chemicals target BC reaction, CT reaction or ACC phosphorylation. This article provides a comprehensive review and updates of ACC inhibitors, with a focus on their therapeutic application in metabolic syndromes and malignant diseases. The patent status of common ACC inhibitors is discussed.
Keywords: Acetyl-CoA carboxylases, cancer, fatty acid synthesis, inhibitors, metabolic syndromes, obesity
Recent Patents on Anti-Cancer Drug Discovery
Title:Targeting Acetyl-CoA Carboxylases: Small Molecular Inhibitors and their Therapeutic Potential
Volume: 7 Issue: 2
Author(s): Di-Xian Luo, Di-Jun Tong, Sandeep Rajput, Chun Wang, Duan-Fang Liao, Deliang Cao and Edmund Maser
Affiliation:
Keywords: Acetyl-CoA carboxylases, cancer, fatty acid synthesis, inhibitors, metabolic syndromes, obesity
Abstract: Acetyl-CoA carboxylases (ACCs) play a rate-limiting role in fatty acid biosynthesis in plants, microbes, mammals and humans. ACCs have the activity of both biotin carboxylase (BC) and carboxyltransferase (CT), catalyzing carboxylation of Acetyl-CoA to malonyl-CoA. In the past years, ACCs have been used as targets for herbicides in agriculture and for drug discovery and development of human diseases, such as microbial infections, diabetes, obesity and cancer. A great number of small molecule ACC inhibitors have been developed, including natural and non-natural (artificial) products. These chemicals target BC reaction, CT reaction or ACC phosphorylation. This article provides a comprehensive review and updates of ACC inhibitors, with a focus on their therapeutic application in metabolic syndromes and malignant diseases. The patent status of common ACC inhibitors is discussed.
Export Options
About this article
Cite this article as:
Luo Di-Xian, Tong Di-Jun, Rajput Sandeep, Wang Chun, Liao Duan-Fang, Cao Deliang and Maser Edmund, Targeting Acetyl-CoA Carboxylases: Small Molecular Inhibitors and their Therapeutic Potential, Recent Patents on Anti-Cancer Drug Discovery 2012; 7 (2) . https://dx.doi.org/10.2174/157489212799972918
DOI https://dx.doi.org/10.2174/157489212799972918 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Update on COX-2 Selective Inhibitors: Chemical Classification, Side Effects and their Use in Cancers and Neuronal Diseases
Current Topics in Medicinal Chemistry Breast Cancer Diagnosis in Digital Mammography Images Using Automatic Detection for the Region of Interest
Current Medical Imaging Antidiabetic Drugs: Mechanisms of Action and Potential Outcomes on Cellular Metabolism
Current Pharmaceutical Design An efficient Synthesis of New Fused Oxazinocarbazoles
Letters in Organic Chemistry Bioactive Herbal Alkaloids as Anti-Infective Agents
Anti-Infective Agents Chemoprevention of Colorectal Carcinogenesis by Natural Anti-Inflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Inflammatory Mediators Hold the Key to Dendritic Cell Suppression and Tumor Progression
Current Medicinal Chemistry PROGRAMMED Cell Clearance: Molecular Mechanisms and Role in Autoimmune Disease, Chronic Inflammation, and Anti-Cancer Immune Responses
Current Immunology Reviews (Discontinued) IL-17 Axis Driven Inflammation in Non-Alcoholic Fatty Liver Disease Progression
Current Drug Targets Ketoprofen Allergic Reactions
Recent Patents on Inflammation & Allergy Drug Discovery Alogliptin; A Review of a New Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Cardiovascular & Hematological Disorders-Drug Targets Prognostic Value of CD34 Positive Cells in the Lumen of Tumor Vessels in Breast Cancer
Current Angiogenesis (Discontinued) Growth Suppression and Mitotic Defect Induced by JNJ-7706621, an Inhibitor of Cyclin-Dependent Kinases and Aurora Kinases
Current Cancer Drug Targets Targeting Cytotoxic Conjugates of Somatostatin, Luteinizing Hormone- Releasing Hormone and Bombesin to Cancers Expressing Their Receptors: A “Smarter” Chemotherapy
Current Pharmaceutical Design Phytosterols and Triterpenoids for Prevention and Treatment of Metabolic-related Liver Diseases and Hepatocellular Carcinoma
Current Pharmaceutical Biotechnology Type 2 Diabetes Mellitus and the Elderly: An Update on Drugs Used to Treat Glycaemia
Current Vascular Pharmacology Regulatory Overview of Biosimilars: Current Scenario and Future Opportunities
Applied Clinical Research, Clinical Trials and Regulatory Affairs In Vivo Bacterial Imaging without Engineering; A Novel Probe-Based Strategy Facilitated by Endogenous Nitroreductase Enzymes
Current Gene Therapy Induction of Apoptosis by Nano-Synthesized Complexes of H2L and its Cu(II) Complex in Human Hepatocellular Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Improved Anti-Tumor Activity of Novel Highly Bioactive Liposome-Bound TRAIL in Breast Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery